1. Scrip
  2. >>Business
  3. >>Earnings

Gilead Teases Big Cancer Drug Readouts In Second Half

 
• By Alaric DeArment

The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.

Cancer cells on scientific background.3d illustration
Gilead announced its second quarter earnings, highlighting developments in virology as well as oncology • Source: Shutterstock

Although antivirals remain the cornerstone of Gilead Sciences, Inc.’s overall business, including its COVID-19 drug Veklury (remdesivir), the second quarter also saw continued significant growth for its oncology business, led by its cell therapies and a recently approved breast cancer drug. The company, which has been focusing on building oncology as a franchise to diversify from antivirals, expects to reveal important cancer data readouts through the end of 2021.

The Foster City, CA-based company announced its second-quarter earnings on 29 July, reporting overall revenues that grew 21% to $6.2bn over the second quarter of 2020, as its HIV and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

More from Business

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.